BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3401042)

  • 1. Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sato T; Takamizawa H; Wiklund B
    Arch Gynecol Obstet; 1988; 243(2):61-8. PubMed ID: 3401042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer.
    Yabushita H; Masuda T; Ogawa A; Noguchi M; Ishihara M
    Gynecol Oncol; 1988 Jan; 29(1):66-75. PubMed ID: 3422208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sekiya S; Takamizawa H; Suzuki N; Tokita H
    Arch Gynecol Obstet; 1988; 243(2):69-81. PubMed ID: 3165255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sato T; Takamizawa H; Wiklund B
    Arch Gynecol Obstet; 1988; 243(1):41-50. PubMed ID: 3165614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
    Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
    Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.
    Panza N; Pacilio G; Campanella L; Peluso G; Battista C; Amoriello A; Utech W; Vacca C; Lombardi G
    Cancer; 1988 Jan; 61(1):76-83. PubMed ID: 2446734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
    Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
    Oishi T; Maruo T; Iwasaki M; Mochizuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
    Avall Lundqvist E; Nordström L; Sjövall K; Eneroth P
    Eur J Gynaecol Oncol; 1989; 10(6):395-405. PubMed ID: 2627971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
    Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Kiviranta A; Hallman K; Holm L; Weiner E; Tamsen L
    Gynecol Oncol; 1990 Oct; 39(1):16-25. PubMed ID: 2227569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin.
    Macchia V; Mariano A; Cavalcanti M; Coppa A; Cecere C; Fraioli G; Elia S; Ferrante G
    Int J Biol Markers; 1987; 2(3):151-6. PubMed ID: 2836526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoembryonic antigen, ferritin, tissue polypeptide antigen, and CA15/3 in breast cancer: relationship between carcinoma and normal breast tissue.
    Gion M; Mione R; Dittadi R; Griggio L; Munegato G; Valsecchi M; Del Maschio O; Bruscagnin G
    Int J Biol Markers; 1986; 1(1):33-8. PubMed ID: 3480322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
    Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Tamsen L
    Gynecol Oncol; 1990 Oct; 39(1):26-33. PubMed ID: 2227570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic antigen, ferritin, and tissue polypeptide antigen in serum and tissue. Relationship with the receptor content in breast carcinoma.
    Gion M; Mione R; Dittadi R; Fasan S; Pallini A; Bruscagnin G
    Cancer; 1986 Mar; 57(5):917-22. PubMed ID: 3943025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of different serum tumor markers in gynecological malignancies.
    Paulick R; Caffier H; Horner G; Lang K; Filbry E
    Cancer Detect Prev; 1985; 8(1-2):115-20. PubMed ID: 4064031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.